{"nctId":"NCT00294515","briefTitle":"IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients","startDateStruct":{"date":"2006-03-31","type":"ACTUAL"},"conditions":["Cytomegalovirus Infections"],"count":326,"armGroups":[{"label":"Valganciclovir up to 100 days","type":"EXPERIMENTAL","interventionNames":["Drug: Valganciclovir"]},{"label":"Valganciclovir up to 200 days","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Valganciclovir"]}],"interventions":[{"name":"Valganciclovir","otherNames":["Valcyte"]},{"name":"Valganciclovir","otherNames":["Valcyte"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* â‰¥ 16 years of age\n* CMV seronegative recipient of primary or secondary renal allograft from a living or cadaveric seropositive donor\n* Adequate hematological and renal function\n* Patients and partners must agree to maintain effective birth control for 90 days following cessation of study medication\n\nExclusion Criteria:\n\n* CMV disease, or receipt of anti-CMV therapy within 30 days prior to screening\n* Multi-organ transplant recipient\n* Hepatitis B, hepatitis C or HIV positive\n* Women who are pregnant or lactating","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Patients Who Developed Cytomegalovirus (CMV) Disease up to Month 12 Post-transplant","description":"Percentage of CMV-seronegative renal transplant recipients (R-) receiving a CMV-seropositive graft (D+) who developed CMV disease (confirmed and assumed) within 12 months post-transplant.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.6","spread":null},{"groupId":"OG001","value":"23.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Developed CMV Disease up to Month 6 Post-transplant","description":"Percentage of CMV-seronegative renal transplant recipients (R-) receiving a CMV-seropositive graft (D+) who developed CMV disease (confirmed and assumed) within 6 months post-transplant.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.2","spread":null},{"groupId":"OG001","value":"10.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Developed CMV Disease up to Month 9 Post-transplant","description":"Percentage of CMV-seronegative renal transplant recipients (R-) receiving a CMV-seropositive graft (D+) who developed CMV disease (confirmed and assumed) within 9 months post-transplant.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.6","spread":null},{"groupId":"OG001","value":"22.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Developed CMV Disease up to Month 18 Post-transplant","description":"Percentage of CMV-seronegative renal transplant recipients (R-) receiving a CMV-seropositive graft (D+) who developed CMV disease (confirmed and assumed) within 18 months post-transplant.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.9","spread":null},{"groupId":"OG001","value":"34.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Developed CMV Disease up to Month 24 Post-transplant","description":"Percentage of CMV-seronegative renal transplant recipients (R-) receiving a CMV-seropositive graft (D+) who developed CMV disease (confirmed and assumed) within 24 months post-transplant.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.5","spread":null},{"groupId":"OG001","value":"34.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":94,"n":164},"commonTop":["Leukopenia","Diarrhoea","Oedema Peripheral","Anaemia","Urinary Tract Infection"]}}}